FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
BUFFALO, N.Y., May 08, 2018 -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that management will present at the Deutsche Bank’s 43rd Annual Health Care Conference in Boston, MA, on Tuesday, May 8th, at 2:10 pm EDT.
The presentation will be webcasted, and can be accessed at the Investor Relations section of the Company’s website, located at www.athenex.com. An archive will be available at this website until August 6, 2018.
About Athenex, Inc.
Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery and development of next generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform and a Global Supply Chain Platform. Athenex’s Oncology Innovation Platform generates clinical candidates through an extensive understanding of kinases, including novel binding sites and human absorption biology, as well as through the application of Athenex’s proprietary research and selection processes in the lab. The Company’s current clinical pipeline is derived from two different platform technologies Athenex calls Orascovery and Src Kinase Inhibition. The Orascovery platform is based on the novel oral P-glycoprotein pump inhibitor molecule HM30181A, through which Athenex is able to facilitate oral absorption of traditional cytotoxics, which Athenex believes may offer improved patient tolerability and efficacy as compared to IV administration of the same cytotoxics. The Orascovery platform was developed by Hanmi Pharmaceuticals and licensed exclusively to Athenex for all major worldwide territories except Korea, which is retained by Hanmi. The Src Kinase Inhibition platform refers to novel small molecule compounds that have multiple mechanisms of action, including the inhibition of the activity of Src Kinase and the inhibition of tubulin polymerization during cell division. Athenex believes the combination of these mechanisms of action provides a broader range of anti-cancer activity as compared to either mechanism of action alone. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments. Athenex has offices in Buffalo and Clarence, New York; Cranford, New Jersey; Houston, Texas; Chicago, Illinois; Hong Kong; Taipei, Taiwan and multiple locations in Chongqing, China.
CONTACT:
Jim Polson
Tel: +1-716-427-2952
Athenex, Inc.
